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Highlights 
 iPSC-derived hepatocyte-like cells (HLCs) rendered traceable in vivo. 
 Reproducible lentivirus-based gene transfer during the differentiation process. 
 Protocol and reporter expression did not negatively impact on HLC maturation. 
 Proof-of-principle shown for whole-body SPECT/CT-afforded HLC in vivo tracking. 
 
  
         
Page | 2 
 
 
 
 
Reporter gene-engineering of human induced pluripotent stem cells during 
differentiation renders in vivo traceable hepatocyte-like cells accessible. 
 
Candice Ashmore-Harris
1,2
, Samuel JI Blackford
2
, Benjamin Grimsdell
1,3
, Ewelina Kurtys
1
, 
Marlies C Glatz
1
, Tamir S Rashid
2,4,$ 
and Gilbert O Fruhwirth
1,$,
*  
 
 
1
Imaging Therapy and Cancer Group, Dept of Imaging Chemistry & Biology, School of 
Biomedical Engineering & Imaging Sciences, St Thomas’ Hospital, King’s College London 
(KCL), London, SE1 7EH, UK 
2 
Centre for Stem Cells & Regenerative Medicine, School of Basic and Medical Biosciences, 
Guy’s Hospital, KCL, London, SE1 9RT, UK 
3
Centre for Human and Applied Physiological Sciences, School of Basic and Medical 
Biosciences, Shepherd’s House, King’s College London, SE1 1UL 
4 
Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, SE5 
9RS, UK 
 
$ 
Senior authors 
 
*Correspondence: Dr Gilbert Fruhwirth (gilbert.fruhwirth@kcl.ac.uk)  
 
Running title: Tracking iPSC-derived HLCs 
         
Page | 3 
 
 
  
         
Page | 4 
 
Abstract 
Primary hepatocyte transplantation (HTx) is a safe cell therapy for patients with liver disease, 
but wider application is circumvented by poor cell engraftment due to limitations in 
hepatocyte quality and transplantation strategies. Hepatocyte-like cells (HLCs) derived from 
human induced pluripotent stem cells (hiPSC) are considered a promising alternative but also 
require optimisation of transplantation and are often transplanted prior to full maturation. 
Whole-body in vivo imaging would be highly beneficial to assess engraftment non-invasively 
and monitor the transplanted cells in the short and long-term. 
Here we report a lentiviral transduction approach designed to engineer hiPSC-derived 
HLCs during differentiation. This strategy resulted in the successful production of sodium 
iodide symporter (NIS)-expressing HLCs that were functionally characterised, transplanted 
into mice, and subsequently imaged using radionuclide tomography. 
Graphical Abstract 
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1. Introduction 
Orthotopic liver transplantation (OLT) is the core treatment for end-stage liver disease and 
some metabolic disorders but patient need consistently exceeds donor organ availability. 
Primary hepatocyte transplantation (HTx) is a well-established, safe cell therapy benefitting 
from reduced invasiveness, retention of the native liver architecture and offering repeat use of 
cryopreserved donor cells (Forbes et al., 2015). Whilst HTx tends to result in relatively short-
term improvement in hepatic function or graft rejection, preconditioning regimes have shown 
improved engraftment pre-clinically, but require optimisation (Soltys et al., 2017). Success of 
HTx engraftment has also been strongly linked to cell quality (Donato et al., 2008; Ibars et 
al., 2016), yet it relies on hepatocytes isolated from livers rejected for OLT  (e.g. geriatric 
donors, prolonged ischaemia, fatty livers). To circumvent HTx quality and supply limitations, 
human induced pluripotent stem cell (hiPSC)-derived hepatocytes have been considered a 
potential substitute. Several protocols were developed to differentiate hiPSCs into 
hepatocyte-like cells (HLCs) (Hannan et al., 2013; Rashid et al., 2010; Si-Tayeb et al., 2010; 
Song et al., 2009). Moreover, clinical-grade hiPSC lines capable of differentiation into HLCs 
(Baghbaderani et al., 2015; Blackford et al., 2018; Wang et al., 2015) accompanied by 
protocols demonstrating clinically relevant scalable HLC or liver organoid production 
(Takebe et al., 2017; Wang et al., 2017; Yamashita et al., 2018) significantly progressed the 
clinical realisation of HLC therapies.  
There is currently no standard protocol for preclinical HLC transplantation in vivo, with 
variations in transplantation site, cell format (single cell suspensions vs. novel formats) and 
stage of differentiation at transplant reported (Asgari et al., 2013; Chen et al., 2015; 
Nagamoto et al., 2016; Pettinato et al., 2016; Takayama et al., 2017; Takebe et al., 2017). 
Post-transplant evaluations typically rely on blood/serum analyses for soluble factors and 
liver enzyme activity, offering no information on the in vivo location of transplanted cells and 
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providing only indirect viability information. Alternatively, histology of biopsied tissues 
demonstrates localised engraftment but is invasive and a risk to both the host and transplanted 
cells. The option to track engrafted cells would be highly beneficial. Non-invasive whole-
body imaging would provide spatiotemporal information about their in vivo location and 
viability both short and long-term and allow quantitative comparison between different 
transplantation strategies.  
In vivo cell tracking can be achieved by directly labelling cells or by employing 
reporter gene technology with the latter offering several advantages; (i) the observation 
period is independent of the contrast agent, i.e. not limited by label efflux or the half-life of a 
radioisotope; (ii) genetic encoding avoids label dilution phenomena and better reflects cell 
viability, and also (iii) circumvents complex direct cell labelling procedures and associated 
toxicities (Fruhwirth et al., 2018; Volpe et al., 2018). Its drawback is the need for genetic 
engineering. Host reporter proteins are preferable to foreign reporters, which are prone to 
recognition/destruction by an intact immune system. Importantly, host reporters should not be 
expressed in the transplanted tissue of interest, and only in a limited number of other host 
tissues, ideally at low levels to ensure favourable contrast during imaging. 
The human sodium iodide symporter (hNIS) is a transmembrane glycoprotein that has 
been exploited as a radionuclide reporter gene for both single photon computed tomography 
(SPECT) and positron emission tomography (PET) in a variety of cell tracking settings; 
including cancer metastasis (Diocou et al., 2017; Fruhwirth et al., 2014; Volpe et al., 2018), 
migration of mesenchymal stem cells (Dwyer et al., 2011), tracking of hiPSC and cardiac 
stem cell myocardial infarction models (Templin et al., 2012; Terrovitis et al., 2008), and 
embryonic stem cell-caused teratomas (Wolfs et al., 2017). hNIS is endogenously expressed 
at high levels in the thyroid gland and at lower levels in few extrathyroidal tissues (salivary 
glands, mammary glands, stomach and small intestine) (Portulano et al., 2014). Its function 
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depends on an intact Na
+
/K
+
 gradient, driven by cellular ATP, and thus it sensitively reports 
only live cells.  
Here, our aim was to develop a protocol for the generation of in vivo traceable HLCs 
during differentiation, to enable compatibility with the range of transplantation protocols 
currently utilised in the field and provide a non-invasive approach to optimise HLC 
engraftment protocols in the future. We assessed the impact of lentiviral gene transfer on 
HLC maturation and provided proof-of-principle in vivo detection of resultant traceable 
hNIS-mGFP
+
 HLCs by SPECT/CT imaging. 
 
2. Material and methods 
2.1 Reagents and chemicals. Purchased from Sigma, Thermo-Fisher, Gibco or StemCell 
Technologies, unless otherwise stated. All cell lines including hiPSC lines have been 
previously described and were grown as recommended (cf. Supplement). Standard in vitro 
methodologies including lentivirus (LV) production, flow cytometry, gene expression 
analysis, secreted albumin and cell viability determinations, cellular radiotracer uptake, and 
immunofluorescence staining are detailed in the Supplement. 
2.2 Cell differentiation. hiPSC colonies from the patient-derived A1ATD
z/z
 (Rashid et al., 
2010; Yusa et al., 2011) or the cGMP derived CGT-RCiB-10 (WCB) hiPSC line (Cell and 
Gene Therapy Catapult, UK), herein referred to as A1AT and CGT10 respectively, were 
differentiated under hypoxic conditions (5% (v/v) O2, 5% (v/v) CO2, 37
o
C) via serial 
introduction of small molecules and growth factors as previously described (Blackford et al., 
2018).  
2.3 Cell transduction. Cells were washed with PBS. Viral particles with an estimated MOI 
of 5* (based on 2x10
6 
cells expected per 10cm dish) were diluted in hepatocyte maturation 
media and added dropwise to cover cells (3mL media/10cm dish). Dishes were left at room 
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temperature for 15 min. 1.5mLfresh medium was added to each dish and cells were incubated 
overnight in hypoxic conditions (5% CO2, 5% O2). 24h later 1.5ml fresh medium was added 
and after 48h the cells were washed and lifted for either re-seeding/in vitro maturation, in 
vivo transplantation, or flow cytometric analysis. 
2.4 Cell preparation for in vivo experiments. For intraperitoneal injection of pre-labelled 
cells, cells were first radiolabelled as for in vitro uptake assays with 100kBq 
99m
TcO4
-
/mL. 
Cells were subsequently washed twice with PBS
++
, lifted using TrypLE and resuspended in 
PBS
++
 at 10
7
cells/100µL. Radiolabelled cells were used immediately for injection into 
animals. 
2.5 Animals. NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG; Charles River UK) were 
maintained under sterile conditions with food and water available ad libitum. All procedures 
were performed in accordance with all legal, ethical, and institutional requirements. 
2.6 In vivo imaging and image analysis. Mice were anesthetized with 2% (v/v) isoflurane in 
pure oxygen and injected either with in vitro labelled HLCs intrahepatically (to set up the 
animal model) and/or with 30 MBq of the NIS-radiotracer 
99m
TcO4
-
 (in 100 µL sterile PBS) 
i/v (to enable in vivo NIS imaging). Animals remained under anesthesia from radiotracer 
administration throughout SPECT/CT scanning. Immediately after intrahepatic HLC 
injection or 45 min after i/v radiotracer administration SPECT imaging was performed over a 
period of 60 min using a preclinical Nanoscan SPECT/CT Silver Upgrade instrument 
(Mediso) equipped with 1 mm collimators. CT image acquisition (55 kVp tube voltage, 
1200 ms exposure time in 360 projections) was performed after tracer administration but 
before SPECT scanning to reduce overall anesthesia duration. Repeat imaging with the same 
radiotracer was not affected by tracer amounts from the first imaging session under these 
conditions as previously demonstrated (Diocou et al., 2017).  
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All SPECT/CT data sets were reconstructed using a Monte Carlo-based full 3D 
iterative algorithm (Tera-Tomo; Mediso). Corrections for attenuation, detector dead time, and 
radioisotope decay were in place as needed. All images were analysed using VivoQuant 
software (inviCRO), enabling the co-registration of SPECT and CT images and delineation of 
regions of interest (ROIs) for quantification of radioactivity. As background can vary in 
different locations in vivo it is important to consider local/regional thresholding and 
segmentation. We employed the 3D implementation of Otsu’s method (Otsu, 1979) for 
rendering volumes with radioactivity counts above background. The total activity in the 
whole animal (excluding the tail) at the time of tracer administration was defined as the 
injected dose (ID). Radioactivity in each ROI was quantified using VivoQuant software and 
expressed as standard uptake value (SUV). 
2.7 Liver histology. Harvested livers were separated into individual lobes, embedded in 
optimal cutting temperature (OCT) medium and frozen in isopentane pre-cooled over liquid 
nitrogen and stored at −80 °C. 10 µm sections were cut with a Cryomatic cryostat (Bright Ltd, 
Huntingdon, UK), placed on polysine-coated slides and fixed in 4% paraformaldehyde 
(15min at room temperature (RT)), washed thrice in PBS before blocked for 1h (PBS 
containing 1.5% bovine serum albumin, 3% donkey serum, 0.1% Triton-X). Sections were 
incubated with goat anti-human albumin antibody (Bethyl laboratories #A80-129A, 
10µg/mL) overnight at 4
o
C, washed thrice in PBS-T (PBS containing 0.1% Tween-20), and 
stained with donkey anti-goat secondary antibody conjugated to Cy3 (Jackson/Stratech, 705-
165-147, 2µg/mL) for 45 minutes at RT. After three PBS-T washes, nuclei were stained with 
Hoechst 33342 (1µg/mL) for 10min at RT, washed another three times in PBS-T, rinsed 
twice in deionized water and mounted (10%(w/v) Mowiol 4-88 containing 2.5%(w/v) 
DABCO). Images were taken on a NIKON Eclipse Ti-E inverted fluorescence microscope 
equipped with a 20x NA0.45 objective lens and filter sets appropriate for imaging Hoechst 
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33342 (cell nuclei) and Cy3 using NIS Elements acquisition software; for image processing 
ImageJ software v1.41 (NIH) was used. 
 
3. Results 
3.1 Generation of in vivo traceable HLCs by transduction during differentiation. 
Established protocols to differentiate hiPSCs into HLCs employ a stepwise approach: 
induction of endoderm, hepatic specification, hepatoblast expansion and hepatic maturation 
(Hannan et al., 2013; Rashid et al., 2010; Si-Tayeb et al., 2010; Song et al., 2009). We used 
two hiPSC lines, A1AT
z/z
 RMA B08 (A1AT) and the cGMP-compliant line CGT-RCiB-10 
(CGT10), which differentiated into HLCs adopting the expected morphology throughout 
(Fig.1A). Briefly, tightly packed hiPSC colonies with a high nuclear-to-cytoplasm ratio and 
prominent nucleoli expanded rapidly from initially seeded colonies following induction of 
endoderm differentiation. Definitive endoderm was stimulated towards hepatic endoderm and 
the resulting hepatoblast population rapidly expanded and proliferated creating a confluent 
monolayer. Subsequently, a polyhedral monolayer of immature HLCs with high cytoplasm-
to-nuclear ratio was obtained. On day 18, we transduced the differentiating cell lines with 
LVs containing DNA encoding for the dual-mode radionuclide-fluorescence reporter gene 
hNIS-mGFP. Transduction at earlier differentiation time points (e.g. day 10) was inefficient 
due to either very low transduction efficiencies (hiPSC stage) or cell loss during transduction 
in the hepatoblast expansion stage (high cell turnover; Fig.S1). 
We validated that differentiation occurred as expected at two differentiation time points 
and compared transduced cells to non-transduced populations from the same differentiation 
batch. The first time point was two days post-transduction (day 20) at the immature HLC 
stage when HLCs are typically passaged onto collagen-I for further maturation in vitro or 
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lifted for in vivo transplantation. Flow cytometry confirmed hNIS-mGFP expression (Fig.1B) 
and comparable expression of the hepatic progenitor marker epithelial cell adhesion molecule 
relative to untransduced control HLCs (EpCAM; Fig.1C). Additional markers of foetal 
hepatocyte development were quantified by quantitative real-time PCR to assess whether the 
hepatic lineage was retained: ɑ-fetoprotein (AFP), cytochrome P450 Family protein 3A7 
(CYP3A7), and hepatic nuclear factor 4α (HNF4A) (Fig.1D-F). No significant differences 
between hNIS-mGFP
+
 HLCs and untransduced control HLCs were observed. Similar results 
were obtained when primary foetal hepatocytes were transduced (Fig.S2). Long-term culture 
of hNIS-mGFP
+
 A1AT HLCs demonstrated morphology, cell viability, and albumin 
production to be comparable to untransduced HLCs, as well as reporter expression to be 
stable for at least 100 days (Fig.S3). 
Following passage of HLCs onto collagen-I, we cultured both hNIS-mGFP
+
 HLCs and 
untransduced control HLCs for two weeks before assessing whether the transduced cell 
population retained the capacity to mature. Most cells exhibited the typical polyhedral 
morphology and cells co-expressing albumin and HNF4A, considered the gold standards for 
bona fide hepatocytes, were seen in abundance along with more immature cells (Fig.2A). We 
further observed that the expected membrane expression of hNIS-mGFP was maintained 
throughout the maturation process with cells capable of co-expressing HNF4A, albumin and 
hNIS, indicating similar levels of maturation of both populations. To verify this 
independently, we analysed media concentrations of secreted albumin by ELISA and 
confirmed them to be similar (Fig.2B). Moreover, expression levels of ALBUMIN and 
HNF4ɑ mRNA were comparable between hNIS-mGFP+ and untransduced HLCs (Fig.2C-D). 
Additionally, we analysed gene expression of the asialoglycoprotein receptor isoform 1 
(ASGR1; Fig.2E), which is typically found on the cell surface of functional mature HLCs 
(Peters et al., 2016). All markers we investigated demonstrated that hNIS-mGFP
+
 HLCs and 
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untransduced HLCs did not differ significantly. This provided evidence that our LV 
transduction strategy did not negatively impact on maturation to the hepatic phenotype in 
these hiPSC lines. Furthermore, hNIS mRNA expression levels were retained at comparable 
levels at day 34 relative to day 20 indicating that reporter expression was stable throughout 
maturation (Fig 2F). 
We next assessed hNIS-mGFP functionality when expressed in transduced HLCs by 
quantifying cellular uptake of the hNIS radiotracer 
99m
TcO4
-
. Both mature (differentiation day 
34, i.e. two weeks post-transduction) hNIS-mGFP
+
 HLC cell lines readily took up the 
radiotracer as compared to untransduced cells (Fig.2G-H). Moreover, 
99m
TcO4
-
 uptake was 
sensitive to competition with the hNIS co-substrate perchlorate, thereby confirming hNIS 
specificity.  
 
3.2 In vivo imaging of hNIS-mGFP
+
 HLCs. 
First, we pre-labelled hNIS-mGFP
+
 CGT10 HLCs in vitro with 
99m
TcO4
-
 
(16.2±4.1kBq/5x10
6 
cells). The cells were harvested, suspended in PBS to a final volume of 
50 µL and injected intra-hepatically into NSG mice, which were imaged by SPECT/CT 
immediately post-injection (Fig.3A). The signal of the pre-labelled hNIS-mGFP
+
 CGT10 
HLCs was clearly visible at the site of injection. Image quantification revealed a total amount 
of 5.2 kBq 
99m
Tc in the thresholded and segmented location, which had a total rendered 
volume of 14.3 mm
3 
(Fig.3B-C). Notably, we twice used the same amount of hNIS-
mGFP
+
 CGT10 HLCs from the same pre-labelled batch, suspended them in a final volume of 
50µL saline in 1.5 mL tubes, but placed them as imaging phantoms alongside the animals’ 
rear legs (Fig.3B-C) as quantification controls. The quantified average 
99m
Tc activity in the 
phantoms was 6.5 kBq within average rendered volumes of 14.8 mm
3
. The ~18% lower 
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radioactive signal in the segmented image in the mouse as compared to the phantoms 
indicates cell loss upon in vivo injection, most likely due to cell dispersal. 
24h later, the animals were re-imaged by SPECT/CT following intravenous (i/v)
 
99m
TcO4
-
 administration to verify if intra-hepatically administered hNIS-mGFP
+
 HLCs were 
detectable in vivo without pre-labelling (Fig.3A). Due to the short half live of 
99m
Tc 
(τ=6.01h), only ~6% of the radioactivity (0.3 kBq) from in vitro labelling was left at the time 
of i/v administration of 
99m
TcO4
-
. Control animals received only the i/v administered 
radiotracer (Fig.3D). 
 99m
TcO4
-
 uptake by hNIS clearly demonstrated reporter function in vivo 
in HLCs and, more importantly, that the administered hNIS-mGFP
+
 CTG10 HLCs were 
detectable in the liver without interference from any organs endogenously expressing mouse 
NIS (homologous to hNIS; Fig. 3; (Portulano et al., 2014)). In vivo image quantification 
revealed HLCs uptake of 25.4 kBq 
99m
Tc in the background-corrected and segmented 
location, which had a total rendered volume of 4.1 mm
3
, a noticeable decrease in size relative 
to the previous scan.
 
Imaging data demonstrated that hNIS-mGFP
+
 CTG10 HLCs remained 
alive for at least 24h post administration, but were undetectable after seven days, most likely 
due to death in the liver environment.  
To verify that this limited cell survival was not due to reporter expression, hNIS-
mGFP
+
 and non-reporter expressing control HLCs from the same batch of differentiation 
were transplanted intra-hepatically on day 23 of the differentiation protocol. We observed 
cell survival by SPECT/CT imaging for 2 days post transplantation into the liver in the hNIS-
mGFP
+ 
HLC population (Fig.4A-C). Following animal sacrifice, we detected in excised 
livers some hNIS-GFP
+
 HLCs (Fig.4D) and confirmed this by histology (Fig.4E; staining for 
human albumin in sections from the transplant sites). Notably, both control and traceable 
HLCs were detected by histology at day 2. Importantly, human albumin (albeit at low levels 
due to the early time point after transplantation) was found in the serum of both animals 
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transplanted with hNIS-mGFP
+
 and control HLCs (Fig.4F). Radioactivity measurements of 
the corresponding organs revealed similar levels in organs endogenously expressing NIS and 
specific uptake in the livers of mice transplanted with hNIS-GFP
+
 HLCs. Similar to the 
results in Fig.3, neither hNIS-mGFP
+
 nor control HLCs from the same transplant cohorts 
were detectable at day 6 (neither by in vivo imaging (Fig.4C) nor by any tissue analyses (data 
not shown)) indicating that both control and hNIS-mGFP
+
 cells exhibit the same limited 
survival behaviour in vivo in this animal model. Comparatively, similarly engineered liver 
cancer cells transplanted subcutaneously or intrahepatically and allowed to establish tumours 
were detectable for at least five weeks (Fig.S4-S5; endpoints determined by animal 
regulations and not by detectability), validating our in vivo tracking approach. This suggests 
that that death of our HLC populations is not due to the method of transplantation, that there 
is no disadvantage for traceable HLCs, but rather that the long-term tracking capacity of the 
traceable liver cancer cells is caused by their inherent survival advantage. 
 
4. Discussion 
Multiple studies, both clinically and preclinically, have aimed to improve the efficacy of HTx 
therapy (Boudechiche et al., 2015; Nagamoto et al., 2016, 2014; Soltys et al., 2017; 
Yamanouchi et al., 2009). Typically, analyses of HTx engraftment are restricted to serial 
biopsies and/or serum samples without the involvement of non-invasive monitoring. This is 
especially problematic for research on: the impact of the transplant site on graft retention; the 
optimal timepoint within differentiation for maximal engraftment/proliferation post-
transplant; the therapeutic benefit/success of suspension cell transplants over novel formats 
(e.g. hepatocyte sheets, liver organoids); or the benefits of repeat infusions/treatment intervals 
on graft retention/therapeutic effect.  
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Here, we demonstrated LV-mediated gene transfer during differentiation, thereby 
introducing the radionuclide-fluorescence reporter hNIS-mGFP into differentiating immature 
iPSC-derived HLCs rendering them traceable in vivo. As LVs efficiently infect non-dividing 
cells, we chose to transduce differentiating cells after the key stages of specification and 
proliferation when HLCs already exhibited the distinctive polyhedral hepatic morphology. 
Transduction during differentiation renders gene transfer compatible with the range of in vivo 
transplantation protocols in the field, crucially including transplantation of HLCs prior to 
final maturation allowing completion of maturation post transplantation (cf. Introduction). 
Resultant hNIS-mGFP
+
 HLCs showed no significant phenotypic changes compared to 
untransduced normally differentiating HLCs (Fig.1) and continued to mature as expected 
(Fig.2).  
Lentiviral transduction results in gene transfer that is not site-specific but also not 
random. It results in polyclonal populations in respect to the genomic insertion position, 
which represents a safety concern for genetic engineering of stem cell therapies. Notably, 
lentiviruses were found to be safer than for example conventional γ-retroviruses (Biffi et al., 
2011). Currently, lentiviruses are the tool of choice to produce several clinically approved 
genetically engineered cell therapies (e.g. anti-cancer chimeric antigen receptor T cell 
therapies). Non-viral alternatives have been developed but often suffer from low transfection 
rates, cell toxicities and/or expression stability (Ramamoorth et al., 2015). Recent genome-
editing methodologies (Maeder et al., 2016) enable site-specific insertion of a reporter and 
thus have the potential to overcome the safety concerns of viral transduction methodologies. 
Another aspect is the differentiation status of the therapeutic cells; the more differentiated 
and hence less pluripotent, the smaller the overall risk associated with viral gene transfer (cf. 
we transduced on day 18 when the differentiating cells were already committed to the hepatic 
lineage and beyond the hepatoblast expansion stage; Fig.1). It is noteworthy that we did not 
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observe any teratoma formation, in contrast we observed HLC loss within less than a week 
(see below). 
Reporter expression was stable and both parts of the fusion reporter hNIS-mGFP were 
functional (Fig.2, Fig.S3) with hNIS-mGFP
+
 HLCs detectable in vivo post intrahepatic 
administration (Fig.3). A week post-administration traceable HLCs were undetectable, likely 
due to HLC death in our animal model, but traceable control tumour cells remained 
detectable for weeks when administered both subcutaneously and intra-hepatically 
demonstrating long-term tracking capability and that death of our HLC population is not due 
to the method of transplantation but rather survival of tumour cells is due to the inherent 
survival advantage of SK-Hep liver cancer cells (Fig.S4-S5). The chosen dual-mode reporter 
permits streamlined preclinical research (convenient cytometry and histology due to 
fluorescent protein presence) with the CGT10 line used in this study suitable for clinical 
translation, highlighting the potential of this system for pre-clinical in vivo tracking of cells 
with therapeutic potential. hNIS, without the mGFP fusion, is also suitable for clinical 
research (for SPECT and PET imaging) and is already used in clinical trials as a reporter gene 
in different contexts (DeGrado, 2016). Similar results were obtained in primary foetal 
hepatocytes (Fig.S2) indicating our findings are not limited to iPSC-derived HLCs.  
To our knowledge this is the first study to introduce hNIS for non-invasive imaging of 
hiPSC-derived HLCs in vivo, and the first to do so during differentiation. Our results 
highlight the retention of the hepatic phenotype in LV-transduced immature HLCs 
throughout their maturation, with stable hNIS-mGFP reporter expression enabling their in 
vivo imaging. This strategy addresses the unmet need for a non-invasive in vivo tracking 
strategy for pre-clinical assessment of HLC transplantation including engraftment 
optimisation studies and provides a promising tool for future clinical research. 
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Figure legends 
 
 
 
Figure 1. Comparison of untransduced and hNIS-mGFP
+
 HLCs 2 days after 
transduction | (A) Scheme depicting the differentiation stages of iPSCs to HLCs (top) 
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combined with micrographs showing the morphologies of both A1AT and CGT10 HLCs at 
the corresponding differentiation stages. Representative live cell flow cytometric analyses of 
differentiating HLCs on day 20 showing (B) GFP signals in transduced HLCs and (C) 
comparable surface marker expression of the hepatic progenitor marker EpCAM. mRNA 
expression analysis (by qRT-PCR) of an immature hepatocyte gene panel 2 days after 
transducing the differentiating cells: (D) EpCAM, (E) Hepatic nuclear factor 4α (HNF4A), 
(F) ɑ-fetoprotein (AFP), and (G) Cytochrome P450 Family 3A7 (CYP3A7). Control and 
transduced cells were always from the same differentiation batches and values normalised to 
corresponding control cells. N=3 biological replicates (i.e. independent differentiations); error 
bars are SEM; two-tailed Student’s t-test was applied (p>0.05 for all). 
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Figure 2. Comparison of untransduced and hNIS-mGFP
+
 HLCs 2 weeks after 
transduction | (A) Immunofluorescence micrographs demonstrating hNIS-mGFP
+ 
cells 
mature following passage and co-express the gold standard markers for hepatic cells, albumin 
and HNF4A. Images representative of 3 independent differentiations. Scale bars 100µm. (B) 
Secreted albumin concentrations are not significantly different between control and 
transduced batches. Similarly, no significant differences were detected for (C-E) marker gene 
expression by qRT-PCR (normalised to corresponding control batches). (F) Day 34 hNIS 
expression by qRT-PCR relative to expression at day 20 demonstrating expression is stable 
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(G-H) hNIS-mGFP function quantified by 
99m
TcO4
-
 uptake relative to untransduced control 
HLCs. The hNIS co-substrate perchlorate served as a 
99m
TcO4
-
 uptake specificity control. 
N=3 biological replicates (with three (B, G-H) or four (C-F) technical repeats per biological 
sample); error bars are SEM (B-F) or SD (G-H). Statistical tests were Students’ t-test (B-F) 
or one-way ANOVA with Tukey’s multiple comparison correction (G-H); “ns” represents 
p>0.05. 
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Figure 3. Non-invasive in vivo imaging of hNIS-mGFP
+
 CGT10 HLCs | (A) Scheme 
depicting the experimental set-up; briefly, 
99m
TcO4
-
-labelled hNIS-mGFP
+
 HLCs were 
administered to NSG mice, animals imaged, and after radiotracer decay re-imaged post 
systemic 
99m
TcO4
-
 injection on the next day. (B/left) SPECT/CT maximum intensity 
projection (MIP) of pre-labelled and intrahepatically administered CGT10 HLC (cf. A/top). 
(B/right) 3D volume rendering of SPECT signals subsequent to local signal/noise 
thresholding (Otsu method) and overlaid onto CT image (blue=cell pellet phantoms; gold=in 
vivo administered cells). (C) SPECT/CT MIP obtained post systemic 
99m
TcO4
-
 injection 
demonstrating intrahepatic detection of hNIS-mGFP
+
 HLCs 24h post cell transplantation but 
cell loss at 7d. Endogenous NIS signals correspond to thyroid/salivary glands (T/S) and the 
stomach (St). (D-E) Naïve animals were SPECT/CT imaged as in C with only endogenous 
murine NIS signals being evident (St=stomach; T/S=thyroid/salivary glands). (F) Image-
derived in vivo biodistribution data (24h post administration) corresponding to n=2 naïve 
control mice and n=4 HLC mice. 
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Figure 4. Intra-hepatically transplanted hNIS-mGFP
+
 HLCs behave similarly 
compared to untransduced HLCs | hNIS-mGFP
+
 and control, non-reporter expressing 
HLCs from the same batch of differentiation were transplanted intrahepatically at day 23 of 
differentiation. (A) Scheme of the in vivo experiment indicating control or hNIS-mGFP
+
 
HLC intrahepatic transplant and 
99m
TcO4
-
-afforded NIS imaging sessions by SPECT/CT 2 
days or 6 days post-transplant. (B/C) SPECT/CT sagittal (left) and transverse (right) slices of 
transplanted mice imaged two days after transplantation. Expected endogenous signals (from 
stomach) are visible in both groups of animals. Importantly, hNIS-mGFP
+
 HLCs were 
detected at the expected location in the liver in corresponding animals two days after 
transplantation (B/green arrows and circle). However, six days post transplantation, no hNIS-
mGFP
+
 HLC were detectable (C). In control animals no signals were recorded at any time, as 
expected (B/C). (D) Standard uptake values (SUV) from relevant tissues determined from in 
vivo images using VivoQuant (Invicro) software. (E) Representative post-mortem liver lobes 
from animals two days after transplantation (matching (B)). Areas containing transplanted 
cells (pale red, brightfield) are visible. Fluorescence excitation (450/20nm BP) paired with a 
camera behind an emission filter (500nm LP) allowed specific visualization of hNIS-mGFP
+
 
HLCs, while untransduced control HLCs were not detectable, confirming cell survival and 
functionality of the hNIS-mGFP
+
 reporter at two days after transplantation. (F) 10µm liver 
sections of snap-frozen livers from corresponding livers in B and D were stained for human 
albumin, indicating presence of human cells alongside mouse liver cells (no human albumin 
staining, different morphology in brightfield). (G) Mouse serum from animals sacrificed two 
days after HLC transplantation was subjected to ELISA analysis for human albumin. Even at 
this early time point after transplantation, ELISA allowed the detection of human serum in 
both reporter-expressing and untransduced animals, confirming the function of the 
transplanted cell at this time point.  
         
